4/A//SEC Filing
Dye Justin 4/A
Accession 0001104659-24-024609
CIK 0001622879other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 6:37 PM ET
Size
10.7 KB
Accession
0001104659-24-024609
Insider Transaction Report
Form 4/AAmended
Dye Justin
Director
Transactions
- Award
Common Stock
2022-11-15$1.57/sh+198,484$311,620→ 489,452 total - Purchase
Common Stock
2023-02-13$1.50/sh+500,000$750,000→ 500,000 total(indirect: See footnote) - Award
Common Stock
2023-09-29+130,801→ 1,616,363 total
Footnotes (5)
- [F1]On November 14, 2022, the reporting person filed a Form 4 that erroneously reported a purchase of 187,484 of shares of Common Stock on November 15, 2022. In fact, as reported in this amendment, the purchase made on November 15, 2022, involved 198,484 shares of common stock. This filing properly reflects the correct number of shares acquired and beneficially owned by the reporting person in and following the reported transaction.
- [F2]The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.34 to $1.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the numbers of shares purchased at each separate price within the range set forth in this footnote.
- [F3]On February 15, 2023, the reporting person filed a Form 4 that erroneously reported a purchase of 500,000 of Common Stock on February 13, 2023, as directly owned by the reporting person. In fact, as reported in this amendment, the purchase made on February 13, 2024, represents shares of common stock held by Dye Capital LLLP ("Dye LLLP"). As the managing partner of Dye LLLP, Mr. Dye has voting and investment control over the securities held by Dye LLLP. Mr. Dye disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein. This filing properly reflects the correct number of shares acquired and beneficially owned by the reporting person in and following the reported transaction.
- [F4]The issuer granted the reporting person shares of common stock with an aggregate value of $103,333 (based on the closing price of the common stock on the OTCQX Best Market on September 29, 2023) for services on the board of directors.
- [F5]On October 6, 2023, the reporting person filed a Form 4 that erroneously reported the Amount of Securities Beneficially Owned Following Reported Transaction of 1,998,863 shares of Common Stock directly owned by the reporting person. In fact, as reported in this amendment, the Amount of Securities Beneficially Owned Following Reported Transaction involved 1,616,363 shares of Common Stock. This filing properly reflects the correct number of shares acquired and beneficially owned, directly, by the reporting person in and following the reported transaction.
Documents
Issuer
Medicine Man Technologies, Inc.
CIK 0001622879
Entity typeother
Related Parties
1- filerCIK 0001654539
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 6:37 PM ET
- Size
- 10.7 KB